Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2835-2845

  Wang, Aiping ^a   Chen, Fang ^a   Wang, Yingjie ^b   Shen, Mingqiang ^a   Xu, Yang ^a   Hu, Jian ^b   Wang, Song ^a   Geng, Fang ^a   Wang, Cheng ^a   Ran, Xinze ^a   Su, Yongping ^a   Cheng, Tianmin ^a   Wang, Junping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 5; ARGININE; CAPSID PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DISEASE COURSE; DRUG POTENCY; EVOLUTIONARY ADAPTATION; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HERPES SIMPLEX VIRUS 2 INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION PREVENTION; MOUSE; MUTAGENESIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS ENTRY;

ALPHA-DEFENSINS; AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; EVOLUTION, MOLECULAR; FEMALE; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; MUTAGENESIS; MUTATION; SEQUENCE ALIGNMENT; VERO CELLS; VIRAL LOAD; VIRUS ATTACHMENT;

EID: 84874734759     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02209-12     Document Type: Article

References (47)

1. Wilson SS, Fakioglu E, Herold BC. 2009. Novel approaches in fighting herpes simplex virus infections. Expert Rev. Anti Infect. Ther. 7:559-568.
2. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.
3. Glynn JR, Crampin AC, Ngwira BM, Ndhlovu R, Mwanyongo O, Fine PE. 2008. Herpes simplex virus type 2 trends in relation to the HIV epidemic in northern Malawi. Sex Transm. Infect. 84:356-360.
4. Piret J, Boivin G. 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 55:459-472.
5. Szyk A, Wu Z, Tucker K, Yang D, Lu W, Lubkowski J. 2006. Crystal structures of human alpha-defensins HNP4, HD5, and HD6. Protein Sci. 15:2749-2760.
6. Bevins CL. 2006. Paneth cell defensins: key effector molecules of innate immunity. Biochem. Soc. Trans. 34:263-266.
7. Com E, Bourgeon F, Evrard B, Ganz T, Colleu D, Jegou B, Pineau C. 2003. Expression of antimicrobial defensins in the male reproductive tract of rats, mice, and humans. Biol. Reprod. 68:95-104.
8. Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, Yip KP, Mok SC. 1998. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am. J. Pathol. 152:1247-1258.
9. Spencer JD, Hains DS, Porter E, Bevins CL, DiRosario J, Becknell B, Wang H, Schwaderer AL. 2012. Human alpha defensin 5 expression in the human kidney and urinary tract. PLoS One 7:e31712. doi:10.1371 /journal.pone.0031712.
10. Ericksen B, Wu Z, Lu W, Lehrer RI. 2005. Antibacterial activity and specificity of the six human alpha-defensins. Antimicrob. Agents Chemother. 49:269-275.
11. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT. 2006. Human alpha-defensins block papillomavirus infection. Proc. Natl. Acad. Sci. U. S. A. 103:1516-1521.
12. Dugan AS, Maginnis MS, Jordan JA, Gasparovic ML, Manley K, Page R, Williams G, Porter E, O'Hara BA, Atwood WJ. 2008. Human alphadefensins inhibit BK virus infection by aggregating virions and blocking binding to host cells. J. Biol. Chem. 283:31125-31132.
13. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, Lehrer RI, Herold BC. 2006. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177:8658-8666.
14. Tanabe H, Ouellette AJ, Cocco MJ, Robinson WE, Jr. 2004. Differential effects on human immunodeficiency virus type 1 replication by alphadefensins with comparable bactericidal activities. J. Virol. 78:11622-11631.
15. Das S, Nikolaidis N, Goto H, McCallister C, Li J, Hirano M, Cooper MD. 2010. Comparative genomics and evolution of the alpha-defensin multigene family in primates. Mol. Biol. Evol. 27:2333-2343.
16. Lynn DJ, Lloyd AT, Fares MA, O'Farrelly C. 2004. Evidence of positively selected sites in mammalian alpha-defensins. Mol. Biol. Evol. 21:819-827.
17. de Leeuw E, Rajabi M, Zou G, Pazgier M, Lu W. 2009. Selective arginines are important for the antibacterial activity and host cell interaction of human alpha-defensin 5. FEBS Lett. 583:2507-2512.
18. Wu Z, Ericksen B, Tucker K, Lubkowski J, Lu W. 2004. Synthesis and characterization of human alpha-defensins 4-6. J. Pept. Res. 64:118-125.
19. Schnölzer M, Alewood P, Jones A, Alewood D, Kent SB. 1992. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 40:180-193.
20. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4:2411-2423.
21. Yasin B, Pang M, Turner JS, Cho Y, Dinh NN, Waring AJ, Lehrer RI, Wagar EA. 2000. Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. Eur. J. Clin. Microbiol. Infect. Dis. 19:187-194.
22. Koch C, Reichling J, Schneele J, Schnitzler P. 2008. Inhibitory effect of essential oils against herpes simplex virus type 2. Phytomedicine 15:71-78.
23. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL. 1994.Amouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest. 70:369-380.
24. McCluskie MJ, Cartier JL, Patrick AJ, Sajic D, Weeratna RD, Rosenthal KL, Davis HL. 2006. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Res. 69:77- 85.
25. Namvar L, Olofsson S, Bergstrom T, Lindh M. 2005. Detection and typing of herpes simplex virus (HSV) in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous for HSV types 1 and 2. J. Clin. Microbiol. 43:2058-2064.
26. Moore JD, Perez-Pardo MA, Popplewell JF, Spencer SJ, Ray S, Swann MJ, Shard AG, Jones W, Hills A, Bracewell DG. 2011. Chemical and biological characterisation of a sensor surface for bioprocess monitoring. Biosens. Bioelectron. 26:2940-2947.
27. Jones J, Whitford W, Wagner F, Kutsch O. 2007. Optimization of HIV-1 infectivity assays. Biotechniques 43:589-590, 592, 594.
28. Ochsenbauer-Jambor C, Jones J, Heil M, Zammit KP, Kutsch O. 2006. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 40:91-100
29. 2006. Homopolyvalent antibody-antigen interaction kinetic studies with use of a dual-polarization interferometric biosensor. Biosens. Bioelectron. 22: 715-721.
30. Tang Y, Mernaugh R, Zeng X. 2006. Nonregeneration protocol for surface plasmon resonance: study of high-affinity interaction with highdensity biosensors. Anal. Chem. 78:1841-1848.
31. Stoddart CA, Nault G, Galkina SA, Thibaudeau K, Bakis P, Bousquet-Gagnon N, Robitaille M, Bellomo M, Paradis V, Liscourt P, Lobach A, Rivard ME, Ptak RG, Mankowski MK, Bridon D, Quraishi .O. 2008. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J. Biol. Chem. 283:34045-34052.
32. Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. 2004. A wide rangeof medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res. 64:119-126.
33. Trybala E, Olofsson S, Mardberg K, Svennerholm B, Umemoto K, Glorioso JC, Bergstrom T. 2004. Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells. Antiviral Res. 62:125-134.
34. Xie C, Prahl A, Ericksen B, Wu Z, Zeng P, Li X, Lu WY, Lubkowski J, Lu W. 2005. Reconstruction of the conserved beta-bulge in mammalian defensins using D-amino acids. J. Biol. Chem. 280:32921-32929.
35. Yasin B, Wang W, Pang M, Cheshenko N, Hong T, Waring AJ, Herold BC, Wagar EA, Lehrer RI. 2004. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J. Virol. 78:5147-5156.
36. Lehrer RI, Jung G, Ruchala P, Andre S, Gabius HJ, Lu W. 2009. Multivalent binding of carbohydrates by the human alpha-defensin, HD5. J. Immunol. 183:480-490.
37. Akhtar J, Shukla D. 2009. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J. 276:7228-7236.
38. Chang TL, Klotman ME. 2004. Defensins: natural anti-HIV peptides. AIDS Rev. 6:161-168.
39. Chang TL, Vargas J, Jr, DelPortillo A, Klotman ME. 2005. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J. Clin. Invest. 115:765-773.
40. Eade CR, Wood MP, Cole AM. 2012. Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development. Curr. HIV Res. 10:61-72.
41. Klotman ME, Chang TL. 2006. Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6:447-456.
42. Rapista A, Ding J, Benito B, Lo YT, Neiditch MB, Lu W, Chang TL. 2011. Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology 8:45.
43. Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ. 2006. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 3:46.
44. Tao W, Richards C, Hamer D. 2008. Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retroviruses 24:925-929.
45. Ding J, Rapista A, Teleshova N, Lu W, Klotman ME, Chang TL. 2011. Mucosal human defensins 5 and 6 antagonize the anti-HIV activity of candidate polyanion microbicides. J. Innate Immun. 3:208 -212.
46. Klotman ME, Rapista A, Teleshova N, Micsenyi A, Jarvis GA, Lu W, Porter E, Chang TL. 2008. Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J. Immunol. 180:6176-6185.
47. Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A. 2003. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 17:F39 -F48. doi:10.1097/00002030-200311070 -00001.